Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back and has not responded to treatment with Bacillus Calmette-Guerin (BCG).
The purpose of this study is to estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab.
Participants will not be paid for their participation.
- IRB Number: 1804004016 (S1605)
- Research Study Identifier: TX8800
- Principal Investigator: Nabil Adra, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required